INTRODUCTION
During platelet aggregation, arachidonic acid is transformed into several oxygenated products now considered to play an important role in hemostasis. These products include prostaglandins G2, H2, and D2 (1-4) as well as the newly discovered thromboxane A2 (5) . Since only trace amounts of free arachidonic acid are found in platelets (6) , the arachidonic acid that is oxygenated during platelet aggregation must be released from complex lipids, and these appear to be Dr. Bills held a fellowship of the Cardeza Foundation during the course of this work.
Received for publication 30 March 1976 and in revised form 21 March 1977. platelet phosphatidylcholine (PC)' and phosphatidylinositol (PI). We have shown that radioactive arachidonic acid is readily incorporated from plasma into the phospholipids of human platelets (7) . When these platelets are washed and treated with thrombin, this radioactive arachidonic acid is released from PC and PI and oxygenated by platelet lipoxygenase and cyclooxygenase, giving rise to radioactive prostaglandins, thromboxane B2 and hydroxy-fatty acids (7) .
The release of arachidonic acid from platelet PC and PI is tlhe result of an endogenous phospholipase activity. The stimulation of this activity must be an early event in the induction of platelet aggregation and the platelet release reaction. We now report on the substrate specificity of this phospholipase activity.
We present evidence here that platelets may have two different phospholipase A2 activities which are stimulated by thrombin, one specifically releases arachidonic acid from PC; the other releases mainly arachidonic acid and trace amounts of other fatty acids from PI and/or phosphatidylserine (PS) . The net effect is a specific release of arachidonic acid in response to thrombin.
METHODS
Fatty acid incorporation-comparative studies. Citrated platelet-rich plasma (40 ml) prepared as described previously (7) was cooled to 40C and EDTA2 was added to give a final concentration of 1 mM. The platelet-rich plasma was centrifuged at 2,000g for 20 min at 4°C. The supernate was discarded and the platelet pellet was resuspended in an equal volume of buffered saline containing EDTA (1 'Abbreviations used in this paper: PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine.
2 EDTA was added to aid in resuspension of platelets. After incubation, the suspensions were cooled at 4°C and EDTA was added to a final concentration of 1 mM. The suspensions were centrifuged at 2,000 g for 20 min at 4°C to yield a pellet containing 98% of the platelets. The supernate, containing unincorporated fatty acids, was removed. The platelets were resuspended in an equal volume of the above buffered saline containing EDTA, but without albumin and then recentrifuged at 2,000 g for 15 min at 40C to yield a pellet containing 98% of the platelets. The platelets were finally resuspended in one-half volume of buffered saline without EDTA or albumin. The lipids from 3-ml samples of these platelet suspensions (containing about 2.0 x 109 platelets) were extracted, separated chromatographically, and then assayed for radioactivity exactly as described elsewhere (7) .
Thrombin-induced changes in 14C-fatty acid-labeled platelets. Suspensions of platelets (3 ml containing about 2.0 x 109 platelets that had incorporated one of the 14C-fatty acids exactly as described above) were treated with either saline or thrombin ( (7) . The lipids from these samples were extracted and separated chromatographically. (Docosanoic acid was added to each sample as an internal standard before extraction). The zones of silica gel from the thin-layer chromatographic plate containing free fatty acids were scraped into columns stoppered with glass wool and the fatty acids were eluted with 10 ml chloroform. A 2-ml sample of the eluent was transferred to a scintillation vial, evaporated, and then assayed for radioactivity. The remainder of the eluent was blown to dryness and the fatty acid methyl esters were prepared as previously described (8) . These methyl esters were separated by gasliquid chromatography using a Barber-Colman instrument (Barber-Colman Co., Rockford, Ill.) fitted with a column packed with 10% Silar-lOC on Gas-Chrom Q. (7) for 60 min at 37°C. The platelets were isolated by centrifugation, washed, and resuspended in buffered saline as described previously (7). Samples of the platelet suspension (3 ml) containing about 4 .0 x 109 platelets were incubated at 37°C for 5 min with either saline or thrombin (5 U/ml). Total lipids were extracted from the samples and phospholipids were isolated by column chromatography (7) . The PC and phosphatidylethanolamine (PE) were resolved by thin-layer chromatography (7) and visualized by means of iodine vapor. Zones of silica gel containing these individual phospholipids were scraped into columns stoppered with glass wool and the phospholipids were eluted with 10 ml methanol. A 4-ml sample was transferred to a scintillation vial, evaporated, and assayed for radioactivity. A second 4-ml sample was assayed for phospholipid phosphorus, which is indicative of either total PC or total PE, by the method of Harris and Popat (9) .
Materials. [1-'4C]Arachidonic, linoleic, and oleic acid (sp act 55 mCi/mM) as well as 10% Silar-lOC on Gas-Chrom Q was purchased from Applied Science Labs, Inc., State College, Pa. [1-14C]8,11,14-Eicosatrienoic acid (sp act 57 mCi/mM) was purchased from New England Nuclear, Boston, Mass. and bovine serum albumin (Fraction V powder, fatty acid poor) from Pentex Biochemical, Kankakee, Ill. Docosanoic acid was purchased from Supelco, Inc., Bellefonte, Pa. All other materials are described elsewhere (7).
RESULTS
Studies of comparative fatty acid incorporation. Table I summarizes the results of experiments in which different radioactive fatty acids were incubated singly with human platelets under identical conditions. Arachidonic acid and 8,11,14-eicosatrienoic acid were readily incorporated into platelets whereas oleic and linoleic acids were poorly incorporated. Of the radioactivity incorporated into platelets, greater than 90% of that of arachidonic acid and 8,11,14-eicosatrienoic acid, and greater than 75% of that of the other fatty acids, was present in phospholipids. 8,11,14-Eicosatrienoic acid was incorporated into platelet triglycerides to a greater extent than the other fatty acids.
Thrombin-induced changes in "C-fatty acidlabeled platelets. When platelets that had incorporated the 14C fatty acids exactly as described above were treated with thrombin, the changes in radioactivity of PC, summarized in Table II In contrast to the selective hydrolysis of ["4C]arachidonyl-PC, a significant decrease in the radioactivity of PS + PI was noted for all of the fatty acids studied (Table III) . The percentage decrease in radioactivity of PS + PI labeled with different fatty acids varied between 14.3 and 24.3% (Table III, column 3) . However, the actual decrease in the radioactivity of these phospholipids was very small when platelets were labeled with the 18 carbon unsaturated fatty acids which were poorly incorporated, and great when they were labeled with the 20 carbon prostaglandin precursors which were readily incorporated. If the amount of radioactive arachidonic acid incorporated into this phospholipid fraction is considered to be 100%, then the relative decreases seen with the 18 carbon unsaturated fatty acids were 0.5 and 1.0% whereas those seen with arachidonic acid and 8,11,14-eicosatrienoic acid were 24.3 and 16.9% respectively (Table III,  column 4) .
No decrease in radioactivity of platelet PE was seen when platelets labeled with any of the fatty acids studied were treated with thrombin.
Thrombin-induced changes in total free fatty acid. When [14C]arachidonic acid-labeled platelets, preincubated with 5,8,11,14-eicosatetraynoic acid, were treated with thrombin there was release of radioactivity from PC and PI as previously reported (7).
In this case, intact [54C]arachidonic acid accumulated since its oxygenation was blocked by 5,8,11,14-eicosatetraynoic acid. The thrombin-induced changes of total platelet free fatty acids are summarized in Table IV plasma at rates that could account for the levels of this fatty acid normally esterified to PC and PI (10). Thus, the major source of the arachidonic acid normally esterified to platelet PC and PI may be free arachidonic acid which is known to circulate in plasma (11) . Since PC and PI are the source of the arachidonic acid that is converted to prostaglandins and thromboxane A2 during thrombin-induced aggregation, both the levels of free arachidonic acid circulating in plasma and the capacity of platelets to esterify this fatty acid to PC and PI would be expected to influence platelet function. The present studies show that radioactive arachidonic acid is incorporated into the phospholipids of washed human platelets at a much greater rate than radioactive linoleic or oleic acids. Since this occurs in the presence of a pool of free linoleic and oleic acids (Table IV) it is possible that the rates of incorporation of all three fatty acids are similar, the specific activity of the arachidonic acid being much higher than that of oleic or linoleic acids.
It has been suggested that the linoleic acid in plasma is normally taken up by platelets, converted into arachidonic acid and then esterified to phospholipids (12) . However, this hypothesis is based on studies of lysates ofhuman platelets and, althouigh such a pathway may exist, our results stuggest that it is of little importance for the prodtuction of the prostaglandins and thromboxane A2. acid before incorporation then a decrease in the amount of radioactivity in platelet PC after thrombin stimulation would have been detected. It was not. Furthermore, "4C-labeled products of platelet lipoxygenase and cyclooxygenase would also have been detected and they were not. This supports our contention that the arachidonic acid released from the phospholipids and utilized by the platelet oxygenation pathways is derived largely from the plasma pool of free arachidonic acid. 8,11,14-Eicosatrienoic acid is normally present at very low levels in both platelet phospholipids (10) and plasma (11) . However, this prostaglandin precursor was readily incorporated into platelet phospholipids. It has been reported that rats and rabbits fed a diet enriched with 8,11,14-eicosatrienoic acid have elevated levels of this fatty acid in their plasmas as well as esterified to platelet phospholipids and triglycerides (13, 14) . Our results suggest that similarly elevated levels would be obtained in platelets if humans were fed a diet enriched with 8,11,14-eicosatrienoic acid. Since this fatty acid is the precursor of prostaglandins known to inhibit platelet aggregation (15, 16) , such a diet may provide a rationale for the prophylaxis of thrombosis.
Platelet phospholipase activities. The thrombin-induced decrease in phospholipid radioactivity in platelets labeled with ['4C]arachidonic acid is due to a stimulated phospholipase activity (7) . Based on the present evidence, we suggest that human platelets contain two phospholipase A2 activities which are stimulated by thrombin. One activity utilizes platelet PC and releases only arachidonic acid. The other activity utilizes platelet PI and/or PS, two phosphatides that are highly enriched with arachidonic acid. It is not yet known whether these activities are due to one or more enzymes.
In our experiments with different "4C-fatty acids, more radioactivity was incorporated into platelet PC than into any other lipid component (Table I) . However, only the PC labeled with [14C]arachidonic acid showed a decrease in radioactivity in response to thrombin (Table II) . Since arachidonic acid has been reported to be esterified almost exclusively at the 2 position of platelet phospholipids (17) this decrease is probably the result of a stimulated phospholipase A2 activity. By contrast, the activity that utilized PI and PS showed no such specificity. When platelets, labeled with different "4C-fatty acids were treated with thrombin, decreases in the radioactivity of these two phospholipids were always seen (Table III) . The actual amount of "4C-fatty acid released was quite small for oleic and linoleic acids because only small amounts of these radioactive fatty acids were present. Further, since both of these platelet phosphatides The studies discussed above demonstrate that radioactive oleic and linoleic acids are not hydrolyzed from platelet PC and PE although trace amounts are released from PI and/or PS. It is possible, however, that pools of platelet phosphatides that were not labeled do release large amounts of these unsaturated fatty acids. We therefore measured the amounts of nonradioactive fatty acids to ascertain whether thrombin induced the release of oleic and linoleic acids from unlabeled, endogenous phospholipid pools. These experiments confirm the tracer studies. Only arachidonic acid was seen to accumulate in response to thrombin. Thus none of the other commonly occurring fatty acids were released from platelet phospholipids in response to thrombin.
All ofthe above findings suggest that human platelets contain a thrombin-stimulated phospholipase A2 activity that utilizes only 1-acyl-2-arachidonyl-PC and changes in total platelet PC should reflect this fact. For example, if 100% of platelet PC contained arachidonic acid at the 2 position, then a thrombin-induced decrease in [14C ]arachidonyl-PC of 25% should be matched by a 25% decrease in total PC (assuming that no reesterification of lyso-PC occurs). However, only about 24-30% of human platelet PC contains arachidonic acid (6, 10) . Therefore, a 25% decrease in Selective Release of Arachidonic Acid in Human Platelets 5 [4C ]arachidonyl-PC should only result in a 25% decrease in this 24-30%o pool if arachidonyl-PC is the only substrate. Thus total PC should only decrease by 6-7.5%. The observed 7.6% decrease in total PC (Table V) therefore supports the above hypothesis. It has been demonstrated that unsaturated fatty acids such as linoleic and oleic acid will both competitively and nonreversibly inhibit prostaglandin cyclooxygenase (18, 19) . If the phospholipase activities stimulated by thrombin were to release these fatty acids, the production of prostaglandins G2 and H2, and thromboxane A2 would be inhibited. The observed selectivity results in the release of large amounts of arachidonic acid, the substrate for platelet cyclooxygenase, and only trace amounts ofthose fatty acids which could inhibit the cyclooxygenase. Thus, the production of the endoperoxides and thromboxane A2 is facilitated.
The selective mechanism involved in the release of arachidonic acid by platelets can be considered to be the initial step in platelet prostaglandin and thromboxane synthesis and may be of importance in hemostasis and thrombosis.
